文献速递白血病

单细胞分析揭示急性髓系白血病对quizartinib的异质性耐药

Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis.
PubMed 文献 · Blood · 2017-05-10

该研究利用患者样本的单细胞和集落靶向测序,分析携带活化FLT3内部串联重复突变的急性髓系白血病患者在获得性quizartinib耐药时的克隆多样性。研究发现多数患者存在大量克隆多样性,表明quizartinib的临床耐药高度复杂,反映了急性髓系白血病潜在的克隆异质性。

要点

  • 单细胞和集落靶向测序揭示quizartinib耐药时存在大量克隆多样性。
  • 多数携带活化FLT3内部串联重复突变的急性髓系白血病患者耐药时呈高度克隆异质性。
  • quizartinib临床耐药高度复杂,反映急性髓系白血病潜在的克隆异质性。

核心结论

  • quizartinib的临床耐药高度复杂,反映了急性髓系白血病潜在的克隆异质性。

研究设计与样本

  • 利用患者样本的单细胞和集落靶向测序,分析携带活化FLT3内部串联重复突变的急性髓系白血病患者在获得性quizartinib耐药时的克隆多样性。

主要发现

  • 在多数携带活化FLT3内部串联重复突变的急性髓系白血病患者中,获得性quizartinib耐药时存在大量克隆多样性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Genomic studies have revealed significant branching heterogeneity in cancer. Studies of resistance to tyrosine kinase inhibitor therapy have not fully reflected this heterogeneity because resistance in individual patients has been ascribed to largely mutually exclusive on-target or off-target mechanisms in which tumors either retain dependency on the target oncogene or subvert it through a parallel pathway. Using targeted sequencing from single cells and colonies from patient samples, we demonstrate tremendous clonal diversity in the majority of acute myeloid leukemia (AML) patients with activating FLT3 internal tandem duplication mutations at the time of acquired resistance to the FLT3 inhibitor quizartinib. These findings establish that clinical resistance to quizartinib is highly complex and reflects the underlying clonal heterogeneity of AML.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Smith CC, Paguirigan A, Jeschke GR, et al. Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. Blood. 2017. PMID: 28490572. doi:10.1182/blood-2016-04-711820

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。